High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study

Australia was one of the first countries with unrestricted access to government subsidized direct-acting antiviral (DAA) therapy for adults with chronic hepatitis C virus. This study assessed real-world DAA treatment outcomes across a diverse range of Australian clinical services and evaluated factors associated with successful treatment and loss to follow-up. Real-world Effectiveness of Antiviral therapy in Chronic Hepatitis C (REACH-C) consisted a national observational cohort of 96 clinical services including specialist clinics and less traditional settings such as general practice. Data were obtained on consecutive individuals who commenced DAAs from March 2016 to June 2019. Effectiveness was assessed by sustained virological response ≥12 weeks following treatment (SVR) using intention-to-treat (ITT) and per-protocol (PP) analyses. Within REACH-C, 10,843 individuals initiated DAAs (male 69%; ≥50 years 52%; cirrhosis 22%). SVR data were available in 85% (9,174 of 10,843). SVR was 81% (8,750 of 10,843) by ITT and 95% (8,750 of 9,174) by PP. High SVR (≥92%) was observed across all service types and participant characteristics. Male gender (adjusted odds ratio [aOR] 0.56, 95% confidence interval [CI] 0.43-0.72), cirrhosis (aOR 0.52, 95% CI 0.41-0.64), recent injecting drug use (IDU; aOR 0.64, 95% CI 0.46-0.91) and previous DAA treatment (aOR 0.50, 95% CI 0.28-0.90) decreased the likelihood of achieving SVR. Multiple factors modified the likelihood of loss to follow-up including IDU ± opioid agonist therapy (OAT; IDU only: aOR 1.75, 95% CI 1.44-2.11; IDU + OAT: aOR 1.39, 95% CI 1.11-1.74; OAT only, aOR 1.36; 95% CI 1.13-1.68) and age (aOR 0.97, 95% CI 0.97-0.98). Conclusion: Treatment response was high in a diverse population and through a broad range of services following universal access to DAA therapy. Loss to follow-up presents a real-world challenge. Younger people who inject drugs were more likely to disengage from care, requiring innovative strategies to retain them in follow-up

Altering growth and maturation of Actinidia chinensis 'Hort16A' fruit by heating individual berries

Cuvettes that heat individual fruits on a kiwifruit vine were used to determine how the characteristics of Actinidia chinensis 'Hort16A` fruit are affected by temperature at various stages of fruit development. Each cuvette fitted around a single kiwifruit and a radiant heating element heated the enclosed fruit. Cuvette temperatures were controlled so that each fruit was kept about 4 degrees C warmer than ambient fruit. Heating individual fruit during the early, mid and late periods of the growing season was found to have some immediate effects, and also effects that persisted until harvest. There was an immediate effect on fruit growth, which was most marked early in the season, and which resulted in larger fruit at harvest. Also, heating fruit early in the season increased the soluble solids content at harvest, as well as inducing more yellow (lower hue angle) and softer fruit at harvest. Heating fruit just prior to harvest increased their final dry matter concentration

Paradoxical effects of temperature in multiple sclerosis.

Six cases of multiple sclerosis are reported in which cold produced a temporary exacerbation of symptoms and signs of the disease. Also, in one case investigated in detail by psychophysical methods, heating produced a paradoxical deterioration in vision and simultaneous improvement in sensory and motor function. The effect of temperature in multiple sclerosis is discussed and a physiological explanation for the paradoxical response to heating is suggested